



S8 Fig. Anterior gradient 3 (AGR3) had no indication function for therapeutic response of taxane and 5-fluoropyrimidines in non-luminal patients or grade III patients. (A) Overall survival (OS) and progression-free survival (PFS) curves of AGR3 highly expressed non-luminal patients with taxane treatment were shown, respectively (upper panel). OS and PFS curves of AGR3 low expressed non-luminal patients with taxane treatment were shown, respectively (lower panel). (B) OS and PFS curves of AGR3 highly expressed non-luminal patients with 5-fluoropyrimidines treatment were

shown, respectively (upper panel). OS and PFS curves of AGR3 low expressed non-luminal patients with 5-fluoropyrimidines treatment were shown, respectively (lower panel). (C) OS and PFS curves of AGR3 highly expressed non-luminal patients of grade I - II with taxane treatment were shown, respectively (upper panel). OS and PFS curves of AGR3 low expressed non-luminal patients of grade I - II with taxane treatment were shown, respectively (lower panel). (D) OS and PFS curves of AGR3 highly expressed non-luminal patients of grade I - II with 5-fluoropyrimidines treatment were shown, respectively (upper panel). OS and PFS curves of AGR3 low expressed non-luminal patients of grade I - II with 5-fluoropyrimidines treatment were shown, respectively (lower panel). (E) OS and PFS curves of AGR3 highly expressed IDC patients of grade III with taxane treatment were shown, respectively (upper panel). OS and PFS curves of AGR3 low expressed IDC patients of grade III with taxane treatment were shown, respectively (lower panel). (F) OS and PFS curves of AGR3 highly expressed IDC patients of grade III with 5-fluoropyrimidines treatment were shown, respectively (upper panel). OS and PFS curves of AGR3 low expressed IDC patients of grade III with 5-fluoropyrimidines treatment were shown, respectively (lower panel).